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gle test. In our opinion, the choice of a diagnostic
strategy comprising sequential tests (conditionally
independent) [2,3] with diﬀerent operative characteris-
tics may be more eﬀective. For the diagnosis of ﬁbro-
sis, a diagnostic ﬂow chart can be designed using an
initial highly sensitive test to rule out the diagnosis
if negative and if positive followed by more speciﬁc
tests to conﬁrm it.
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Drs. Colli and Fraquelli underscore several important
implications of our analysis of non-invasive liver ﬁbrosis
test validity [1,2]. The central ﬁnding is that limitations
in the validity of an imperfect gold standard obviate pre-
cise characterization of the validity of surrogates. When
applied to the liver biopsy, our calculations demonstrate
that a perfect marker of liver ﬁbrosis could not be distin-
guished from what many consider to be a clinically
unacceptable one, unless the biopsy sensitivity and spec-
iﬁcity are above 90%. The degree to which error in the
biopsy might aﬀect the apparent validity of a surrogate
should always be considered in non-invasive marker
research.
Drs. Colli and Fraquelli make an excellent observa-
tion about the use of test results in medical management.
Clinicians interpret a single test result in light of the out-
come of other tests, their intrinsic validities, the pre-test
probability of the condition, and many other consider-
ations. Our study does not address the integration of
these multiple factors but rather the simple interpreta-
tion of a substitute for a single test. A logical extension
of our study would be to assess the performance of
multiple diagnostic tests (e.g., serum marker panel and
elastography). In addition, liver biopsy provides infor-
mation on other factors like steatosis that cannot be
ascertained from some non-invasive surrogates, and
our computations do not account for these added diag-
nostic beneﬁts. Likewise, Drs. Colli and Fraquelli cor-
rectly point out that our data showing the limitationsin the traditional way that surrogate markers are evalu-
ated does not answer the pressing clinical question of
what to do when there is a diﬀerence. Fortunately,
non-invasive markers are increasingly being assessed in
clinical trials of hepatitis C treatment. Results of these
studies, and others employing alternative ‘gold stan-
dards’ like the natural history of disease, will be neces-
sary to improve our use of pre-treatment testing to
manage patients with chronic hepatitis C.
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